Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Teva Pharmaceutical Industries Ltd. Earnings Release 2009

Jan 19, 2010

7082_rns_2010-01-19_96ade7f8-cf60-45fd-aa50-f8a21ac3bf26.pdf

Earnings Release

Open in viewer

Opens in your device viewer

TEVA

TEVA PHARMACEUTICAL INDUSTRIES LTD.

Website: www.tevapharm.com

Contact: Elana Holzman Kevin Mannix Teva Pharmaceutical Industries Ltd. Teva North America 972 (3) 926-7554 (215) 591-8912

For Immediate Release

Teva to Report Fourth Quarter and Full Year 2009 Financial Results on February 16, 2010

Jerusalem, Israel, January 19, 2010 – Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it will release its fourth quarter and full year 2009 financial results on Tuesday, February 16, 2010.

Teva will host a conference call and live webcast on the same day, at 8:30 a.m. ET to discuss its fourth quarter and full year 2009 results and overall business environment. A Question & Answer session will follow this discussion. The earnings release will be available on Teva's web site at www.tevapharm.com prior to the call.

Investors and other interested parties may access a live webcast through Teva's website at www.tevapharm.com. Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software. Following the conclusion of the call, a replay of the webcast will be available within 24 hours on the Company's website. Alternatively, a replay of the call can be accessed until February 23, 2009, at 11:59 p.m. ET, by calling (201) 612-7415 outside the U.S. or (877) 660-6853 in the U.S. The Pass Code to access the replay: account #3055 and conference ID #342952.

About Teva

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative pharmaceuticals and active pharmaceutical ingredients. Over 80 percent of Teva's sales are in North America and Western Europe.